Mr. Dane Stevens reports

RECENT US EXECUTIVE ORDER NAMED IBOGAINE COMPOUNDS AMONG THE PSYCHEDELIC THERAPIES PRIORITIZED FOR ACCELERATED FDA REVIEW AND EXPANDED PATIENT ACCESS

Optimi Health Corp. is providing an update on its recently announced ibogaine initiative. Optimi has secured naturally derived ibogaine from two sources, in both hydrochloride (HCl) and freebase form. Development work on the finished drug product is anticipated to commence this summer at the company's GMP facility in British Columbia.

"We are seeing a growing number of research institutions interested in ibogaine and there is real public funding behind it now, including the $50-million program in Texas," said Dane Stevens, chief executive officer and co-founder of Optimi. "We are excited to develop and supply this product from Canada, where we have the facility, the licensing and the experience to make it into standardized pharmaceutical dosages."

Two dosage sizes, 50 milligrams and 100 mg, are planned in encapsulated format. The in-house development program covers standard operating procedures (SOPs) for finished drug encapsulation, dosage strengths, bottling, labelling and packaging, alongside validation of the company's manufacturing and analytical testing methods. The company will provide an update upon completion of the program.

On April 18, 2026, a U.S. executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated Food and Drug Administration review and expanded patient access and directed federal funding to match state investments in psychedelic research. This has intensified attention on ibogaine and on the need for a reliable, GMP-grade supply.

In Canada, ibogaine is not a controlled substance under Canada's Controlled Drugs and Substances Act; rather, it is regulated under the Food and Drugs Act (Canada) and is listed on Health Canada's Prescription Drug List. In contrast, ibogaine remains a Schedule I substance in the United States. Combined with Optimi's GMP infrastructure and current Health Canada licensing, this regulatory environment positions Canada and Optimi specifically, as an advantageous base for the compliant manufacture and supply of ibogaine to support research and regulated access.

ibogaine is a naturally occurring alkaloid derived from the root bark of the Tabernanthe iboga shrub, native to Central and West Africa. It has been studied for its potential to interrupt opioid withdrawal and craving and for its effects on substance-use disorders, posttraumatic stress disorder (PTSD) and traumatic brain injury (TBI). A 2024 Stanford-led study of U.S. special operations veterans, published in Nature Medicine, reported reductions in PTSD, depression, anxiety and functional disability in a cohort following a single ibogaine treatment protocol.

Optimi is developing its ibogaine product at the company's wholly owned GMP facility, which it also uses to manufacture psilocybin and MDMA. The company supplies finished drug products and active pharmaceutical ingredients for clinical research and regulated patient access. Inquiries regarding product for special access programs and clinical trial supply may be directed to sales@optimihealth.ca.

About Optimi Health Corp.

Optimi Health is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia.

We seek Safe Harbor.